---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-103772"
form_type: "8-K"
ticker: "PFSA"
cik: "0001859807"
company_name: "Profusa, Inc."
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:25:00.223123+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Profusa targets $200-$250M revenue by 2030, EU Lumee oxygen launch in Q2 2026

## Summary
- EU Lumee tissue oxygen monitoring launch expected early Q2 2026 after CE marking late Q1 2026.
- 2026 revenue projected $0.5–$2M; 2027 revenue $9–$13M; 2030 revenue $200–$250M.
- US oxygen launch planned for Q1 2027; EU glucose monitoring mid-2027.
- Estimates 35% European population coverage through intended distribution channels.
- Targets $10.5B tissue oxygen market and >500M glucose monitoring population.

## SEC filing metadata
- accession: 0001213900-25-103772
- form_type: 8-K
- ticker: PFSA
- cik: 0001859807
- company_name: Profusa, Inc.
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859807/000121390025103772/0001213900-25-103772-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859807/000121390025103772/ea0263091-8k_profusa.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-103772
- JSON: https://secwatch.observer/filing/0001213900-25-103772.json
- Plain text: https://secwatch.observer/filing/0001213900-25-103772.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.